Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois; Center for Food Allergy and Asthma Research, Institute for Public Health and Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Center for Food Allergy and Asthma Research, Institute for Public Health and Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Ann Allergy Asthma Immunol. 2023 Nov;131(5):645-654.e2. doi: 10.1016/j.anai.2023.08.017. Epub 2023 Aug 24.
Epidemiologic data on coconut allergy remains sparse in the United States despite the labeling requirement by the Food Allergen Labeling and Consumer Protection Act for products containing coconut.
To provide current estimates of the prevalence, severity, determinants, and distribution of coconut allergy in the United States.
A comprehensive food allergy prevalence survey was administered to a nationally representative, probability-based sample of US households between October 1, 2015 and September 30, 2016. Eligible respondents included adults who were able to complete self- and parent-proxy report surveys in English or Spanish by means of web or phone.
Using survey responses from 78,851 individuals, 0.39% (95% confidence interval [CI], 0.33-0.45) of the US general population were categorized as having convincing coconut allergy. Among children, 0.22% (95% CI, 0.16-0.30) were estimated to have coconut allergy compared with 0.43% (95% CI, 0.37-0.51) of adults, whereas only 0.12% (95% CI, 0.08-0.18) of these children and 0.20% (95% CI, 0.16-0.24) of adults with convincing immunoglobulin E (IgE)-mediated coconut allergy reported physician-confirmed diagnoses. A current epinephrine prescription was reported by 40.1% (95% CI, 33.3-47.4) of those with convincing coconut allergy. Reactions involving multiple organ systems were reported by 47.5% (95% CI, 40.1-54.9) of those with convincing coconut allergy.
Roughly 1 in 260 Americans report symptoms consistent with an IgE-mediated allergy to coconut, although fewer than half of these individuals report receiving a physician diagnosis. Our data indicate that most individuals with reported coconut allergy meeting symptom-based criteria for convincingly IgE-mediated disease have comorbid FAs, and for many patients, clinical management seems to be suboptimal.
尽管《食品过敏原标签和消费者保护法案》要求含有椰子的产品必须贴上标签，但美国的椰子过敏流行病学数据仍然很少。
提供目前美国椰子过敏的患病率、严重程度、决定因素和分布的最新估计。
在 2015 年 10 月 1 日至 2016 年 9 月 30 日期间，对美国全国代表性的、基于概率的家庭样本进行了一项全面的食物过敏患病率调查。合格的受访者包括能够通过网络或电话用英语或西班牙语完成自我和父母代理报告调查的成年人。
利用来自 78851 人的调查答复，美国一般人群中有 0.39%（95%置信区间[CI]，0.33-0.45）被归类为有明确的椰子过敏。在儿童中，估计有 0.22%（95%CI，0.16-0.30）有椰子过敏，而成年人则有 0.43%（95%CI，0.37-0.51），其中只有 0.12%（95%CI，0.08-0.18）的儿童和 0.20%（95%CI，0.16-0.24）的成年人有明确的免疫球蛋白 E（IgE）介导的椰子过敏报告有医生确诊的诊断。有明确椰子过敏的人中有 40.1%（95%CI，33.3-47.4）报告了目前有肾上腺素处方。有明确椰子过敏的人中有 47.5%（95%CI，40.1-54.9）报告了涉及多个器官系统的反应。
大约每 260 名美国人报告的症状与 IgE 介导的椰子过敏一致，尽管其中不到一半的人报告接受了医生的诊断。我们的数据表明，大多数报告有椰子过敏并符合基于症状的明确 IgE 介导疾病标准的患者都有共患的食物过敏，而且对许多患者来说，临床管理似乎并不理想。
